Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Hong Kong
· Delayed Price · Currency is HKD 36.86
-0.44 (-1.18%)
Apr 29, 2026, 4:08 PM HKT
HKG:3692 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 15,028 | 12,261 | 10,104 | 9,382 | 9,935 | Upgrade
|
| Revenue Growth (YoY) | 22.57% | 21.35% | 7.69% | -5.56% | 14.32% | Upgrade
|
| Cost of Revenue | 1,519 | 1,117 | 1,033 | 870.19 | 870.39 | Upgrade
|
| Gross Profit | 13,509 | 11,144 | 9,071 | 8,512 | 9,065 | Upgrade
|
| Selling, General & Admin | 4,736 | 4,508 | 4,241 | 4,148 | 4,371 | Upgrade
|
| Research & Development | 3,358 | 2,702 | 2,097 | 1,693 | 1,797 | Upgrade
|
| Other Operating Expenses | 15.13 | 31.98 | 53.9 | 63.73 | 75.91 | Upgrade
|
| Operating Expenses | 8,108 | 7,242 | 6,392 | 5,905 | 6,244 | Upgrade
|
| Operating Income | 5,401 | 3,902 | 2,679 | 2,607 | 2,821 | Upgrade
|
| Interest Expense | -3.16 | -6.69 | -66.68 | -58.14 | -52.82 | Upgrade
|
| Interest & Investment Income | 1,098 | 1,046 | 1,020 | 331.52 | 253.85 | Upgrade
|
| Earnings From Equity Investments | - | - | -2.12 | -13.86 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -44.06 | 21.43 | 4.57 | 44.56 | -9.31 | Upgrade
|
| Other Non Operating Income (Expenses) | 111.08 | 87.35 | 105.25 | 117.17 | 139.34 | Upgrade
|
| EBT Excluding Unusual Items | 6,563 | 5,050 | 3,741 | 3,029 | 3,152 | Upgrade
|
| Gain (Loss) on Sale of Investments | -16.71 | 61.27 | 158.22 | 67.58 | 144.49 | Upgrade
|
| Gain (Loss) on Sale of Assets | 4.3 | 5.72 | 2.1 | 11.24 | 3.94 | Upgrade
|
| Asset Writedown | - | -31.98 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | -134.71 | -159.12 | - | Upgrade
|
| Pretax Income | 6,551 | 5,085 | 3,766 | 2,948 | 3,300 | Upgrade
|
| Income Tax Expense | 995.12 | 713.36 | 488.65 | 364.68 | 587.18 | Upgrade
|
| Net Income | 5,555 | 4,372 | 3,278 | 2,584 | 2,713 | Upgrade
|
| Net Income to Common | 5,555 | 4,372 | 3,278 | 2,584 | 2,713 | Upgrade
|
| Net Income Growth | 27.07% | 33.39% | 26.85% | -4.76% | 5.61% | Upgrade
|
| Shares Outstanding (Basic) | 5,963 | 5,930 | 5,925 | 5,916 | 5,921 | Upgrade
|
| Shares Outstanding (Diluted) | 5,981 | 5,950 | 6,020 | 5,929 | 5,998 | Upgrade
|
| Shares Change (YoY) | 0.52% | -1.16% | 1.52% | -1.14% | 2.04% | Upgrade
|
| EPS (Basic) | 0.93 | 0.74 | 0.55 | 0.44 | 0.46 | Upgrade
|
| EPS (Diluted) | 0.93 | 0.73 | 0.52 | 0.44 | 0.44 | Upgrade
|
| EPS Growth | 26.42% | 40.62% | 19.65% | -1.29% | 1.21% | Upgrade
|
| Free Cash Flow | - | 3,640 | 2,897 | 2,468 | 2,117 | Upgrade
|
| Free Cash Flow Per Share | - | 0.61 | 0.48 | 0.42 | 0.35 | Upgrade
|
| Dividend Per Share | 0.388 | 0.316 | 0.193 | 0.088 | 0.073 | Upgrade
|
| Dividend Growth | 22.73% | 63.53% | 118.47% | 20.84% | 12.44% | Upgrade
|
| Gross Margin | 89.89% | 90.89% | 89.78% | 90.72% | 91.24% | Upgrade
|
| Operating Margin | 35.94% | 31.83% | 26.52% | 27.79% | 28.39% | Upgrade
|
| Profit Margin | 36.97% | 35.66% | 32.44% | 27.54% | 27.31% | Upgrade
|
| Free Cash Flow Margin | - | 29.69% | 28.67% | 26.31% | 21.31% | Upgrade
|
| EBITDA | 5,777 | 4,278 | 3,025 | 2,932 | 3,084 | Upgrade
|
| EBITDA Margin | 38.44% | 34.89% | 29.94% | 31.25% | 31.04% | Upgrade
|
| D&A For EBITDA | 375.57 | 375.57 | 345.63 | 324.37 | 263.42 | Upgrade
|
| EBIT | 5,401 | 3,902 | 2,679 | 2,607 | 2,821 | Upgrade
|
| EBIT Margin | 35.94% | 31.83% | 26.52% | 27.79% | 28.39% | Upgrade
|
| Effective Tax Rate | 15.19% | 14.03% | 12.97% | 12.37% | 17.79% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.